Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study

Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study

Abstract Objectives We assessed the virologic efficacy of switching to co-formulated elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (E/C/F/TDF) in patients with controlled HIV infection. Methods We conducted a retrospective multicenter observational cohort study including adu...

Full description

Bibliographic Details
Main Authors: Nathalie De Castro, Alexandre Brun, Pierre Sellier, Gwenn Hamet, Frédéric Mechaï, Valérie Garrait, Amélie Chabrol, Marie-Anne Bouldouyre, Eric Froguel, Didier Troisvallets, Pauline Caraux-Paz, Constance Delaugerre, Willy Rozenbaum, Jean-Michel Molina
Format: Article
Language:English
Published: BMC 2023-01-01
Series:AIDS Research and Therapy
Subjects:
E/C/F/TDF
switch
virologic efficacy
integrase resistance
Online Access:https://doi.org/10.1186/s12981-022-00499-4

Internet

https://doi.org/10.1186/s12981-022-00499-4

Similar Items